Patents Issued in October 12, 2004
  • Patent number: 6803355
    Abstract: Detergent compositions are formulated with a mixture of hydrophobically modified cellulose polymers or oligomers and cyclic amine based polymers or oligomers. The cellulose/amine mixture maintains the integrity and appearance of fabrics laundered in the compositions. Dye maintenance and anti-pilling benefits are provided. The compositions are provided in containers which alert the user of the benefits provided by the compositions.
    Type: Grant
    Filed: August 3, 2001
    Date of Patent: October 12, 2004
    Assignee: The Procter & Gamble Company
    Inventors: Rajan Keshav Panandiker, Jennifer Leupin Moe, William Conrad Wertz
  • Patent number: 6803356
    Abstract: A method for the preparation of polymers derived from acrolein and including poly(2-propenal, 2-propenoic acid), characterised in that the polymers are exposed to the presence of water, whereby such polymers exhibit increased antimicrobial activity. The polymers may be heated in the range of 40 to 150° C. Further, the polymers may be prepared in the presence of polyethylene glycols, polyols and/or alkanols.
    Type: Grant
    Filed: November 8, 2001
    Date of Patent: October 12, 2004
    Assignee: Chemeq Ltd.
    Inventors: Graham John Hamilton Melrose, Gerry Daly, Andrew James Huxham
  • Patent number: 6803357
    Abstract: The present invention provides methods and compositions for modification and regulation of GLP 1 metabolism, glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoproteinemia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis. The compositions described herein are high-affinity boronyl and non-boronyl peptidomimetic inhibitors of DPIV.
    Type: Grant
    Filed: January 5, 2001
    Date of Patent: October 12, 2004
    Assignees: New England Medical Center Hospitals, Inc., Trustees of Tufts College, 1149336 Ontario Inc.
    Inventors: William A. Bachovchin, Andrew G. Plaut, Daniel Drucker
  • Patent number: 6803358
    Abstract: The present invention provides a protein having an A chain of a ricin-like toxin, a B chain of a ricin-like toxin and a heterologous linker amino acid sequence, linking the A and B chains. The linker sequence contains a cleavage recognition site for a disease specific protease such as a cancer, fungal, viral or parasitic protease. The invention also relates to a nucleic acid molecule encoding the protein and to expression vectors incorporating the nucleic acid molecule. Also provided is a method of inhibiting or destroying mammalian cancer cells, cells infected with a virus, a fugus, or parasites, or parasites utilizing the nucleic acid molecules and proteins of the invention and pharmaceutical compositions for treating human cancer, viral infection, fugal infection, or parasitic infection.
    Type: Grant
    Filed: April 14, 2000
    Date of Patent: October 12, 2004
    Assignee: Twinstrand Therapeutics Inc.
    Inventor: Thor Borgford
  • Patent number: 6803359
    Abstract: The glutamic acid residue of corticotropin-releasing hormone analogs have had the position 20 amino acid residue replaced with a D-amino acid moiety. The resulting CRH analogs do not significantly lower blood pressure but have anti-proliferative actions in cell culture and inhibit experimental cancer growth in animals (mice and rats). Novel applications of such analogs are described, such as to inhibit abnormal cell proliferation for conditions such as cancer, including melanoma, and for inflammatory dermatoses, such as psoriasis.
    Type: Grant
    Filed: November 19, 2001
    Date of Patent: October 12, 2004
    Assignees: The Regents of the University of California, Loyola University of Chicago
    Inventors: Edward T. Wei, Andrzej T. Slominski
  • Patent number: 6803360
    Abstract: Provided are antisense oligonucleotides directed against the raf-1 gene, Ha-ras gene and HER-2 gene, components of a signal transduction pathway involving oncogenes and their normal counterparts and leading to the phenotype of cellular radioresistance. Administration of these antisense oligonucleotides is shown to reverse the radioresistance phenotype in cells overexpressing HER-2 or a mutant form of Ha-ras. Methods and compositions for reversing radiation resisting among other conditions involving these genes are disclosed.
    Type: Grant
    Filed: November 21, 2000
    Date of Patent: October 12, 2004
    Assignee: Georgetown University
    Inventors: Esther H. Chang, Kathleen F. Pirollo
  • Patent number: 6803361
    Abstract: Disclosed and claimed is the use of a liquid jet intradermal administration apparatus that administers a composition: without a needle; and in the epidermis, dermis and/or hypodermis, such as a Pigjet apparatus, for administering bovine vaccines or immunogenic compositions, especially bovine plasmid vaccines or immunogenic compositions. Accordingly, the invention involves bovine immunogenic or vaccine compositions in such an apparatus, and methods for vaccinating bovines or for inducing an immunogenic response in bovines employing such an apparatus, as well as the apparatus containing bovine immunogenic or vaccine compositions.
    Type: Grant
    Filed: February 15, 2002
    Date of Patent: October 12, 2004
    Inventors: Franciscus Antonius Maria Rijsewijk, Remco Siebren Schrijver, Johannes Theodorus Van Oirschot
  • Patent number: 6803362
    Abstract: Heterocyclic compounds and methods of making them and using them.
    Type: Grant
    Filed: March 8, 2002
    Date of Patent: October 12, 2004
    Assignee: Ortho-McNeil Pharmaceutical inc.
    Inventors: Nicholas I. Carruthers, Wenying Chai, Curt A. Dvorak, James P. Edwards, Cheryl A. Grice, Jill A. Jablonowski, Lars Karlsson, Haripada Khatuya, Jennifer D. Kreisberg, Annette K. Kwok, Timothy W. Lovenberg, Kiev S. Ly, Barbara Pio, Chandravadan R. Shah, Siguan Sun, Robin L. Thurmond, Jianmei Wei, Wei Xiao
  • Patent number: 6803363
    Abstract: The present invention contemplates the addition of 0.5% to 4% taurolidine into solutions used peritoneal dialysis. The taurolidine is intended to prevent or reduce the incidence of infection within the abdomen and/or in the vicinity of an implanted dialysis port. The invention also includes methods using solutions of taurolidine in the flushing and locking of catheters and fluid lines used in peritoneal dialysis.
    Type: Grant
    Filed: May 31, 2002
    Date of Patent: October 12, 2004
    Assignee: ND Partners, LLC
    Inventor: Hans-Dietrich Polaschegg
  • Patent number: 6803364
    Abstract: The present invention is concerned with the compounds of formula (I), a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine or a stereochemically isomeric form thereof, wherein p is 0 to 4; q is 0 to 5; X is O, S, NR3 or a direct bond; or —X—R2 is CN; R1 is H, OH, halo, NH2, mono- or di(C1-4alkyl)NH2, C1-6alkyl, C1-6alkylO, C3-7cycloalkyl, aryl, arylC1-6alkyl, NH2C1-4akyl, mono- or di(C1-4alkyl)NH2C1-4akyl or mono- or di(C1-4alkyl)NH2C1-4alkylNH2; R2 is aryl, Het1, optionally substituted C3-7cycloalkyl, optionally substituted C1-6alkyl; R3 is H or C1-4alkyl; R4 and R5 are —C(═O)—Z—R14, C1-6alkyl, halo, polyhaloC1-6alkyl, OH, mercapto, C1-6alkylO, C1-6alkylthio, C1-6alkylC(═O)O, aryl, cyano, nitro, Het3, R6, NR7R8 or C1-4alkyl substituted with —C(═O)—Z—R14, Het3, R6 or NR7R8; Z is O, S, NH, —CH2O or —CH2—S—; R14 is H, C1-20acyl, optionally substituted C1-20alkyl, optionally substituted C3-20alkenyl, C3-2
    Type: Grant
    Filed: August 29, 2001
    Date of Patent: October 12, 2004
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Eddy Jean Edgard Freyne, Frederik Dirk Deroose, Jean Fernand Armand Lacrampe, Werner Constant Johan Embrechts, Jerome Michel Claude Fortin
  • Patent number: 6803365
    Abstract: The invention relates to imidazo[1.3.5]triazinones, a method for their production and methods of use, in particular as inhibitors of cyclic GMP metabolizing phosphodiesterases.
    Type: Grant
    Filed: November 4, 2002
    Date of Patent: October 12, 2004
    Assignee: Bayer Aktlengesellschaft
    Inventors: Ulrich Niewöhner, Helmut Haning, Thomas Lampe, Mazen Es-Sayed, Gunter Schmidt, Erwin Bischoff, Klaus Dembowsky, Elisabeth Perzborn, Karl-Heinz Schlemmer
  • Patent number: 6803366
    Abstract: Disclosed is an agent for improving learning and/or memory, which is useful for therapy of dementia accompanying disorder of memory due to a cerebrovascular disease, neurodegenerative disease such as Alzheimer's disease, endocrine disease, nutritional or metabolic disorder, infectious disease, drug addiction or the like. The agent for improving learning and/or memory according to the present invention comprises as an effective ingredient an isoquinoline derivative having a specific structure, such as (4aR, 12aR)-2-methyl-4a-(3-hydroxyphenyl)-1,2,3,4,4a,5,12,12a-octahydro-quinoline[2,3-g]isoquinoline or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 30, 2002
    Date of Patent: October 12, 2004
    Assignee: Toray Industries, Inc.
    Inventors: Kuniaki Kawamura, Hiroshi Nagase, Noriyuki Hirano, Junzo Kamei
  • Patent number: 6803367
    Abstract: A substance for inducing apoptosis represented by specific formulae. A pharmaceutical composition which can be used for an anticancer agent containing said substance.
    Type: Grant
    Filed: October 1, 2002
    Date of Patent: October 12, 2004
    Assignee: Takara Shuzo Co., Ltd.
    Inventors: Tatsuji Enoki, Nobuto Koyama, Katsushige Ikai, Ikunoshin Kato
  • Patent number: 6803368
    Abstract: Compounds of the formula useful for treatment of disorders of the dopaminergic system, such as schizophrenia, schizoaffective disorder, bipolar disorder, Parkinson's disease, L-DOPA induced pychoses and dyskinesias, Tourette's syndrome and hyperprolactinemia and in the treatment of drug addiction such as the addiction to ethanol, nicotine or cocaine and related illnesses.
    Type: Grant
    Filed: April 23, 2002
    Date of Patent: October 12, 2004
    Assignee: Wyeth
    Inventors: Gary P. Stack, James A. Nelson
  • Patent number: 6803369
    Abstract: A method of modulating the activity of a aberrant cell topoisomerase enzyme involving contacting the enzyme with a compound that inhibits enzyme-mediated cleavage of a polynucleotide substrate with which the enzyme is in complex. Pharmaceutical compositions containing such compounds may be used to treat neoplasias or to inhibit the growth of certain cancer cells. Screening methods can be employed to identify other compounds for these uses.
    Type: Grant
    Filed: July 25, 2001
    Date of Patent: October 12, 2004
    Assignees: SmithKline Beecham Corporation, SmithKlineBeecham p.l.c.
    Inventors: Symon G. Erskine, Michael Gwynn, Neil David Pearson, Edwina Imogen Wilding
  • Patent number: 6803370
    Abstract: Disclosed are certain alpha amino acid compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
    Type: Grant
    Filed: July 20, 2001
    Date of Patent: October 12, 2004
    Assignees: Elan Pharmaceuticals, Inc., Wyeth
    Inventors: Andrei W. Konradi, Michael A. Pleiss, Eugene D. Thorsett, Susan Ashwell, Gregory S. Welmaker, Anthony Kreft, Dimitrios Sarantakis, Darren B. Dressen, Francine S. Grant, Christopher Semko, Ying-Zi Xu
  • Patent number: 6803371
    Abstract: The present invention relates to 2-N-substituted 6-(4-methoxybenzylamino)-9-isopropylpurines that inhibit, inter alia, protein kinases, G-proteins and polymerases. In addition, the present invention relates to methods of using such 2-N-substituted 6-(4-methoxybenzylamino)-9-isopropylpurines to inhibit protein kinases, G-proteins, polymerases and other cellular processes and to treat cellular proliferative diseases.
    Type: Grant
    Filed: January 27, 2003
    Date of Patent: October 12, 2004
    Assignees: The Regents of the University of California, Centre National de la Recherche
    Inventors: Nathanael S. Gray, Peter Schultz, Sung-Hou Kim, Laurent Meijer
  • Patent number: 6803372
    Abstract: Compounds of the general formula (I): wherein Ar1 represents optionally substituted aryl or heteroaryl; n represents 0 or 1; T, U, V, and W each independently represent nitrogen atom or optionally substituted methine group, where at least two of them represent the said methine group; X represents methine or hydroxy substituted methine; Y represents an optionally substituted imino or oxygen atom are described and claimed. These novel spiro compounds are useful as neuropeptide Y receptor antagonists and as agents for the treatment of various kinds of cardiovascular disorders, central nervous system disorders, metabolic diseases and the like.
    Type: Grant
    Filed: March 8, 2002
    Date of Patent: October 12, 2004
    Assignee: Banyu Pharmaceutical Co., Ltd.
    Inventors: Takehiro Fukami, Akio Kanatani, Akane Ishihara, Yasuyuki Ishii, Toshiyuki Takahashi, Yuji Haga, Toshihiro Sakamoto, Takahiro Itoh
  • Patent number: 6803373
    Abstract: A combination of 9,10-dihydro-5-methoxy-9-oxo-N-[4-[2-(1,2,3,4-tetrahydro-6,7,-dimethoxy-2-isoquinolinyl)ethyl]pheny]-4-acridinecarboxamide or a salt thereof and paclitaxel and its analogs or derivatives.
    Type: Grant
    Filed: September 3, 2002
    Date of Patent: October 12, 2004
    Assignee: SmithKline Beecham Corporation
    Inventor: Jan H. M. Schellens
  • Patent number: 6803374
    Abstract: A series of compounds of Formula I are disclosed which are useful in treating viral hepatitus C.
    Type: Grant
    Filed: August 27, 2003
    Date of Patent: October 12, 2004
    Assignee: Bristol-Myers Squibb Company
    Inventors: Eldon Scott Priestley, Carl P. Decicco, Thomas W. Hudyma, Xiaofan Zheng
  • Patent number: 6803375
    Abstract: Compounds, preparations and methods for immunosuppressive treatment of autoimmune disorders, graft rejection and/or graft/host disease. Therapeutically effective amounts of certain substituted triarylmethane compounds, such as 1-[(2-chlorophenyl)diphenylmethyl]-1H-pyrazole, are administered to mammalian patients to selectively inhibit the calcium-activated K+ channel (IKCa1) in lymphocytes, monocytes, macrophages, platelets or endothelial cells without concomitant inhibition of P450-dependent enzyme systems, resulting in reduction of antigen-, cytokine-, or mitogen-induced calcium entry through store operated calcium channels in these cells, suppression of cytokine production by these cells, and inhibition of activation of these cells. Such inhibition of the Ca++ activated K+ channel (IKCa1) prevents the pre-Ca++ stage of cell activation and thus causes immunosuppression and an anti-inflammatory response.
    Type: Grant
    Filed: January 6, 2000
    Date of Patent: October 12, 2004
    Assignee: The Regents of the University of California
    Inventors: K. George Chandy, Heike Wulff
  • Patent number: 6803376
    Abstract: This invention relates, in part, to newly identified methods of using quinolone antibiotics, particularly a gemifloxacin compound against certain pathogenic bacteria, particularly quinolone resistant S. pnemoniae and rare H. influenzae strains.
    Type: Grant
    Filed: May 12, 2000
    Date of Patent: October 12, 2004
    Assignee: SmithKline Beecham Corporation
    Inventors: Peter C. Appelbaum, Kim L. Credito, Todd Davies, Diane B. Hoellman, Linda M. Kelly, Glenn A. Pankuch
  • Patent number: 6803377
    Abstract: The present invention provides compositions for controlling plant pests, containing the compound of the formula (I) and at least one fungicidally active compound, except for tebuconazole, cyclopropylcarboxamides and azolylmethylcycloalkanes.
    Type: Grant
    Filed: June 26, 2002
    Date of Patent: October 12, 2004
    Assignee: Bayer Aktiengesellschaft
    Inventors: Christoph Erdelen, Wolfram Andersch, Klaus Stenzel, Astrid Mauler-Machnik, Wolfgang Krämer
  • Patent number: 6803378
    Abstract: Novel diketoacid compounds of Formula I are provided which are useful as HIV integrase inhibitors and for the treatment of AIDS or ARC.
    Type: Grant
    Filed: September 25, 2002
    Date of Patent: October 12, 2004
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael A. Walker, Timothy D. Johnson, Nicholas A. Meanwell, Jacque Banville
  • Patent number: 6803379
    Abstract: The invention relates to the treatment of viral, bacterial, parasitic, proliferative diseases, neurodegenerative diseases, inflammatory diseases, immunological diseases, transplanted organ rejection, and diseases produced by intoxication with heavy metals. The invention relates to the use of specific metal chelating agents including, furoic acid, 2-thiophenecarboxylic acid and their derivatives, analogs and structurally related chemicals as pharmacological agents that can be used effectively to disrupt and inactivate specific transition metal ion containing zinc finger structural motifs in metalloproteins and specific transition metal ion containing catalytic sites in metalloproteinases, which in turn, inactivate the pathogenic virus, pathogenic prokaryotic or eukaryotic cells which produces disease conditions. The preparations can be administered topically or for systemic use.
    Type: Grant
    Filed: June 4, 2002
    Date of Patent: October 12, 2004
    Inventors: Jose A. Fernandez-Pol, Sebastian Fernandez-Pol
  • Patent number: 6803380
    Abstract: 5-aryl-1H-triazole compounds of the formula are potent and selective COX-2 inhibitors. The invention further relates to pharmaceutical compositions containing these compounds.
    Type: Grant
    Filed: May 17, 2002
    Date of Patent: October 12, 2004
    Assignee: Laboratoire Theramex
    Inventors: Jean-Claude Pascal, Denis Carniato
  • Patent number: 6803381
    Abstract: The present invention relates to compounds of formula wherein R1 is hydrogen or lower alkyl; R2, R2′ are each independently hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl; X is O, S or two hydrogen atoms not forming a bridge; A1/A2 is phenyl; B is a group of formula  wherein R3 is lower alkyl, lower alkenyl, lower alkinyl, benzyl, lower alkyl-cycloalkyl, lower alkyl-cyano, lower alkyl-pyridinyl, lower alkyl-lower alkoxy-phenyl, lower alkyl-phenyl, which is optionally substituted by lower alkoxy, or phenyl, which is optionally substituted by lower alkoxy, or lower alkyl-thienyl, cycloalkyl, lower alkyl-trifluoromethyl or lower alkyl-morpholinyl; Y is —O—, —S— or a bond; and Z is —O—; or a pharmaceutically acceptable salt thereof. These compounds are useful for the control or prevention of acute and/or chronic neurological disorders.
    Type: Grant
    Filed: May 14, 2003
    Date of Patent: October 12, 2004
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Konrad Bleicher, Vincent Mutel, Eric Vieira, Jürgen Wichmann, Thomas Johannes Woltering
  • Patent number: 6803382
    Abstract: The invention relates to novel 1-oxaspiro[2,5]octan-6-ol derivatives of general formula (I): and also to a method for preparing them, and to their use in pharmaceutical compositions for use in human or veterinary medicine, or in cosmetic compositions.
    Type: Grant
    Filed: November 8, 2002
    Date of Patent: October 12, 2004
    Assignee: Galderma Research & Development, S.N.C.
    Inventors: Jacques Eustache, Jean-Guy Boiteau, Céline Tarnus, Vincent Rodeschini, Pierre Van De Weghe
  • Patent number: 6803383
    Abstract: Compounds which inhibit tumor growth and angiogenesis, of general formula (II) are provided. These compounds include glycyl lysine derivatives bound to a central aromatic linking core.
    Type: Grant
    Filed: September 27, 2002
    Date of Patent: October 12, 2004
    Assignee: The Scripps Research Institute
    Inventors: Dale L. Boger, David A. Cheresh
  • Patent number: 6803384
    Abstract: A compound of formula Id and pharmaceutically acceptable salts and esters thereof, wherein the substituent designations are as provided in the specification. Compounds of the invention are useful for treating reperfusion injury.
    Type: Grant
    Filed: January 22, 2003
    Date of Patent: October 12, 2004
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Nader Fotouhi, Paul Gillespie, Robert William Guthrie, Sherrie Lynn Pietranico-Cole, Weiya Yun
  • Patent number: 6803385
    Abstract: Hydroxyeicosatetraenoic acid esters and methods of their use in treating dry eye disorders are disclosed.
    Type: Grant
    Filed: April 4, 2003
    Date of Patent: October 12, 2004
    Assignee: Alcon, Inc.
    Inventors: Peter G. Klimko, Mark R. Hellberg, John R. Falck, Raymond E. Conrow
  • Patent number: 6803386
    Abstract: The present invention is directed to a pharmaceutical composition containing a cancer-treating effective amount of a class of prostacyclin derivatives, and a pharmaceutically acceptable carrier, and to kits and methods of employing the same for the treatment of cancer.
    Type: Grant
    Filed: January 16, 2002
    Date of Patent: October 12, 2004
    Assignee: United Therapeutics Corporation
    Inventors: Robert Shorr, Martine Rothblatt
  • Patent number: 6803387
    Abstract: A compound of formula I or a pharmaceutically acceptable salt thereof in which R1 and R2 are independently H or methyl (for example N,N-dimethyl-1-[1-(4-chlorophenyl) cyclobutyl]-3-methylbutyl amine hydrochloride optionally in the form of its monohydrate) is used for treating fibromyalgia or neuropathic pain, such as pain associated with diabetes mellitus, shingles, nerve injury and varied peripheral neuropathies.
    Type: Grant
    Filed: March 17, 2000
    Date of Patent: October 12, 2004
    Assignee: Abbott GmbH & Co. KG
    Inventors: Carl M. Mendel, Timothy B. Seaton, Steve P. Weinstein, Edward Chong
  • Patent number: 6803388
    Abstract: The invention relates to substituted aryl and heteroaryl (R)-Chiral Halogenated 1-Substitutedamino-(n+1)-Alkanol compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Novel high yield, stereoselective processes for the preparation of the chiral substituted alkanol compounds from chiral and achiral intermediates are described. Preferred (R)-Chiral 1-Substitutedamino-(n+1)-Alkanol compounds are substituted (R)-Chiral N,N-bis-phenyl aminoalcohols. A preferred specific (R)-Chiral N,N-bis phenyl aminoclcohol is the compound.
    Type: Grant
    Filed: December 12, 2001
    Date of Patent: October 12, 2004
    Assignee: Pfizer, Inc.
    Inventors: James A. Sikorski, Richard C. Durley, Margaret L. Grapperhaus, Mark A. Massa, Emily J. Reinhard, Yvette M. Fobian, Michael B. Tollefson, Lijuan Wang, Brian S. Hickory, Monica B. Norton, William F. Vernier, Deborah A. Mischke, Michele A. Promo, Ashton T. Hamme, Dale P. Spangler, Melvin L. Rueppel
  • Patent number: 6803389
    Abstract: This invention discloses a process for producing a polyester resin, which is transparent, substantially free of occurrence of foreign matters or filtration residue, and is subject to no problem in physical properties, within short time, by concurrently reacting polyester whose chief starting material is terephthalic acid and which has been recovered from waste materials and regenerated; a polyhydric alcohol component and a polybasic acid component, at such ratios that the regenerated polyester occupies 10-80% by weight based on the total weight of the regenerated polyester, polyhydric alcohol component and polybasic acid component.
    Type: Grant
    Filed: August 13, 2001
    Date of Patent: October 12, 2004
    Assignee: Kansai Paint Co., Ltd.
    Inventors: Chicara Kawamura, Isamu Takabayashi
  • Patent number: 6803390
    Abstract: Polyurethane foams are made using a prepolymer that is the reaction product of an organic polyisocyanate, a hydroxy-functional acrylate or methacrylate, and a polyol. This prepolymer is reacted at specified volume ratios and isocyanate indices with a polyol component that includes at least one polyol. The foam is made in the presence of a blowing agent and catalyst. Preferred blowing agents are water and chemical blowing agents that generate carbon dioxide in the reaction. Preferred catalysts have primary or secondary amine groups that allow them to react into the resulting polymer structure, thus decreasing the level of volatile components.
    Type: Grant
    Filed: March 29, 2002
    Date of Patent: October 12, 2004
    Assignee: Dow Global Technologies Inc.
    Inventors: Huzeir Lekovic, Ali J. El-Khatib, Frank V. Billotto
  • Patent number: 6803391
    Abstract: Ethylene copolymer elastomer compositions, acrylate rubber compositions, nitrile rubber compositions, fluoroelastomer compositions, and chlorinated olefin elastomer compositions are provided which are curable by exposure to UV radiation. The compositions are particularly suited for production of elastomeric seals using hot melt equipment and a gasketing in place technique.
    Type: Grant
    Filed: September 20, 2002
    Date of Patent: October 12, 2004
    Assignee: DuPont Dow Elastomers, LLC
    Inventors: Patrick Luigi Paglia, Christian Ruepping
  • Patent number: 6803392
    Abstract: Aqueous storage-stable, non-sedimenting photoinitiator suspensions comprising (a) a mono- or bis-acylphosphine oxide of formula (I), wherein R1 is C1-C20alkyl; C2-C20alkyl interrupted by one or more O atoms; C1-C12alkoxy; phenyl-C1-C4alkyl; or phenyl that is unsubstituted or substituted by C1C20alkyl, C1-C12alkoxy, halogen, cyclopentyl, cyclohexyl, C2-C12alkenyl, C2-C18alkyl interrupted by one or more O atoms, and/or by phenyl-C1-C4alkyl; or R1 is biphenylyl; R2 is an aromatic radical or has one of the meanings give for R1; R3 and R4 are each independently of the other C1-C12alkyl, C1-C12alkoxy or halogen; and R5 is hydrogen, C1-C12alkyl, C1-C12alkoxy or halogen; (b) a dispersant; and (c) water are suitable especially in the photopolymerisation of aqueous formulations comprising ethylenically unsaturated monomers.
    Type: Grant
    Filed: March 18, 2002
    Date of Patent: October 12, 2004
    Assignee: Ciba Specialty Chemicals Corporation
    Inventors: Manfred Köhler, Beat Michael Aebli, Martin Holer, Ernst Eckstein, Jean-Pierre Wolf
  • Patent number: 6803393
    Abstract: Multicomponent system curable thermally and with actinic radiation, comprising A) an isocyanate-reactive binder comprising A1) at least one unsaturated polyester whose molecule contains on average at least one group that can be activated with actinic radiation, of the formulae I, II and/or III wherein n is an integer from 1 to 10; and A2) at least one binder, different than (A1), whose molecule comprises on average at least two isocyanate-reactive functional groups, and/or A3) at least one binder, different than (A1), whose molecule comprises on average at least one isocyanate-reactive functional group and at least one reactive functional group having at least one bond that can be activated with actinic radiation, and B) a crosslinker comprising B1) at least one polyisocyanate and/or B2) at least one polyisocyanate whose molecule comprises on average at least one reactive functional group having at least one bond that can be activated with actinic radiation.
    Type: Grant
    Filed: December 11, 2002
    Date of Patent: October 12, 2004
    Assignee: BASF Coatings AG
    Inventors: Rainer Blum, Maxime Allard
  • Patent number: 6803394
    Abstract: A composition for actinic radiation curable nail coatings and artificial nail tips comprising a BISGMA based urethane resin, an additional polymer, a photoinitiator, and having a viscosity of greater than approximately 80,000 cps. Composition may additionally comprise other additives known in the art and also methods of application of the composition alone and with related compositions.
    Type: Grant
    Filed: May 21, 2002
    Date of Patent: October 12, 2004
    Assignee: Gel Products, Inc.
    Inventors: Pamela H. Lilley, Sarah Peterson
  • Patent number: 6803395
    Abstract: Disclosed is an ink composition which comprises water, a colorant, and a lightfastness agent which is a polysiloxane having thereon a hydrophilic moiety and a lightfastness moiety. Also disclosed are printing processes using the ink.
    Type: Grant
    Filed: November 15, 2001
    Date of Patent: October 12, 2004
    Assignee: Xerox Corporation
    Inventors: Thomas W. Smith, Kathleen M. McGrane
  • Patent number: 6803396
    Abstract: Aqueous superplasticizer solutions for concrete compositions include a polymeric superplasticizer and an air-detraining effective amount of a block polyether containing ethylene oxide and propylene oxide units.
    Type: Grant
    Filed: August 16, 2001
    Date of Patent: October 12, 2004
    Assignee: BASF Corporation
    Inventors: Sridhar Gopalkrishnan, Kenneth L. Zack, Karl-Heinz Buechner
  • Patent number: 6803397
    Abstract: A thermoplastic molding composition containing a (co)polymer of vinylcyclohexane and a stabilizer system is disclosed. The stabilizer system contains lactone, sterically hindered phenol and a phosphite compound. The composition that is characterized by its improved thermal stability is suitable for the preparation of molded articles, including optical data carriers.
    Type: Grant
    Filed: August 16, 2001
    Date of Patent: October 12, 2004
    Assignee: Bayer Aktiengesellschaft
    Inventors: Volker Wege, Konstadinos Douzinas, Friedrich-Karl Bruder
  • Patent number: 6803398
    Abstract: An olefin-based thermoplastic elastomer composition comprising a thermoplastic elastomer blended with other resins and rubbers is provided. The thermoplastic elastomer contains polypropylene resin and an olefin-based copolymer rubber, and optionally, a linear polyethylene resin, and the thermoplastic elastomer has been crosslinked to a gel content of 95% or higher. A polyolefin resin, an olefin-based copolymer rubber and a softening agent are further blended with optional inorganic filler to provide the olefin-based thermoplastic elastomer composition. This composition is excellent in oil resistance and extrudability, and well-adapted for use as an energy-saving, resources-saving elastomer in applications including surface or skin material in autoparts, industrial mechanical parts, electric and electronic parts, and construction materials.
    Type: Grant
    Filed: February 28, 2000
    Date of Patent: October 12, 2004
    Assignees: Mitsui Chemicals, Inc., Toyota Motor Corporation
    Inventors: Yuichi Ito, Hiroyasu Yamaoka, Akira Uchiyama, Chika Kako, Hideo Nishimura, Junzo Ukai
  • Patent number: 6803399
    Abstract: Silicone liquid crystals, silicone vesicles, and silicone gels are formed by combining (i) an amine functional silicone or an organic amine compound, (ii) an organic epoxide containing at least two epoxy groups or an epoxy functional silicone containing at least two epoxy groups, and (iii) a fluid such as water, a silicone fluid other than a silicone used in (i) and (ii), and a polar organic compound or nonpolar organic compound other than organic compounds used in (i) and (ii) in which the polar and nonpolar organic compound are present at a concentration to provide a level of solids less than 40 percent by weight based on the weight of (i)-(iii). These silicone liquid crystals, silicone vesicles, and silicone gels are useful in personal care for preparing various skin, hair, and underarm products.
    Type: Grant
    Filed: June 19, 2003
    Date of Patent: October 12, 2004
    Assignee: Dow Corning Corporation
    Inventors: Michael Salvatore Ferritto, Zuchen Lin, William James Schulz, Jr.
  • Patent number: 6803400
    Abstract: Water-swellable hot-melt adhesives based on a tackifying resin, a water-dispersible EVA wax, an ethylene/acrylic ester copolymer, a water-soluble homo- or co-polymer and a super absorber polymer powder having an average particle size of less than 80 &mgr;m display a clearly improved swelling behavior in comparison with the prior art. Furthermore, the swelling agent is significantly more homogeneously distributed in the matrix. Such hot-melt adhesives are suitable for ensuring longitudinal water impermeability in modern cable structures, as water-swellable jointing compounds in the building industry in the area of building conservation and restoration. Such hot-melt adhesives are further suitable for the manufacture of absorbent textile fabrics in the personal hygiene sector.
    Type: Grant
    Filed: March 30, 2001
    Date of Patent: October 12, 2004
    Assignee: Henkel Kommanditgesellschaft auf Aktien
    Inventors: Ruediger Butterbach, Ulricke Maassen, Siegfried Kopannia
  • Patent number: 6803401
    Abstract: A halogen scavenging system is provided for inhibiting the corrosion-causing tendency and coloration of halogen-containing olefin polymers or copolymers, comprising incorporating about 0.01% to about 1% of a hydroltalcite-like solid solution having the formula Al2(Mg)a(OH)b(CO3)c(G)d.eH2O and a crystallite size in the <003> direction of about 190 Å to about 225 Å, and having bidentate coordination for carbonate ion as shown by an infrared spectrum, and wherein 3≦a≦5.5; 8≦b≦14; 1.2≦c≦3; 0≦d≦1; 1≦e≦10 and G is a surface active agent into the halogen containing olefin polymer.
    Type: Grant
    Filed: September 21, 2001
    Date of Patent: October 12, 2004
    Assignee: Reheis, Inc.
    Inventors: Jawahar C. Parekh, Rajanikant D. Desai
  • Patent number: 6803402
    Abstract: Elastomer molded article for semiconductor production apparatuses which is obtained by crosslinking and molding a crosslinkable fluorine-containing elastomer composition comprising a crosslinkable fluorine-containing elastomer component and fine particles of aluminum oxide having an average particle size of not more than 0.5 &mgr;m. The elastomer molded article is excellent in plasma resistance and an amount of micro particles generated after irradiation of plasma is very small and therefore a very clean molded article for semiconductor production apparatuses, particularly a sealing material to be used in an environment of plasma irradiation is provided.
    Type: Grant
    Filed: October 29, 2001
    Date of Patent: October 12, 2004
    Assignee: Daikin Industries, Ltd.
    Inventors: Katsuhiko Higashino, Masanori Hasegawa, Hiroyuki Tanaka, Tsuyoshi Noguchi
  • Patent number: 6803403
    Abstract: A polymer emulsion with good film forming property, which is mixed a synthetic polymer emulsion containing the polymer having the particle size of 0.15 &mgr;m or longer in diameter and a synthetic polymer emulsion containing the polymer having particle size of 0.10 &mgr;m or shorter in diameter, wherein the glass transition temperature of the latter polymer is at least 20 degree lower than that of the former emulsion and the particle size ratio between the former polymer and the latter polymer is 2 or more. The polymer emulsion is used for making moisture-proof coated paper and/or recyclable-coated paper.
    Type: Grant
    Filed: February 28, 2002
    Date of Patent: October 12, 2004
    Assignee: Shinto Fine Co., Ltd.
    Inventor: Takamasa Ishihara
  • Patent number: 6803405
    Abstract: The invention relates to the aqueous preparation of a polymer. Said preparation contains a copolymer consisting of a) 30 to 79.5 wt. % N-vinylpyrrolidone, b) 20 to 69.5 wt. % vinylacetate, c) 0.5 to 25 wt % of a monovinyl ester of a C4 to C20 monocarboxylic acid and d) 0 to 40 wt. % of an additional, copolymerisable, ethylenically unsaturated compound.
    Type: Grant
    Filed: March 29, 2002
    Date of Patent: October 12, 2004
    Assignee: BASF Aktiengesellschaft
    Inventors: Klaus Schnell, Michael Kerber, Eberhard Schupp, Eckehardt Wistuba